Technology ID

Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach

Lead Inventor
Kwong, Peter (NIAID)
Verardi, Raffaello (NIAID)
Chuang, Gwo-Yu (NIAID)
Tsybovsky, Yaroslav (Leidos Biomedical Research, Inc (was SAIC-Frederick, Inc (Science Applications)
Gorman, Jason (NIAID)
Ou, Li (NIAID)
Lindesmith, Lisa (University of North Carolina, Chapel Hill)
Baric, Ralph (University of North Carolina, Chapel Hill)
Georgiou, George (Board of Regents, The University of Texas System)
Research Materials
Therapeutic Areas
Development Stages
Pre-clinical (in vivo)
Lead IC

This technology includes a novel advancement in developing vaccines targeting norovirus, tailored specifically for a more robust and effective response. It centers around an improved version of Virus-Like Particles (VLPs) uniquely engineered for greater stability and efficacy. These enhanced VLPs are designed to remain intact even when faced with the body's immune responses, overcoming a key limitation of previous vaccine designs. This stability is crucial in ensuring the vaccine's effectiveness, particularly in individuals with more robust immune systems who have shown limited response to traditional vaccines. Additionally, the modified VLPs are likely more resistant to degradation, making them a more reliable and durable solution in vaccination campaigns. This innovation could be a significant step in offering a more effective vaccine option for widespread use.

Commercial Applications
  • Enhanced Norovirus Vaccination: Specially designed to improve the effectiveness of vaccines against norovirus, particularly in individuals with previously low response rates to traditional vaccines.
  • Broad-Scale Immunization Programs: Suitable for large-scale public health initiatives due to its increased stability and durability, potentially reducing the frequency of booster shots.
  • Platform for Future Vaccine Development: The stabilization techniques used in this technology could be applied to other vaccine formulations, paving the way for more robust and effective vaccines against various pathogens.
Competitive Advantages
  • Provides enhanced stability and efficacy in norovirus VLP vaccines, ensuring effectiveness even in individuals with strong immune responses who have previously shown limited vaccine response.
  • Its innovative design increases the VLPs' resistance to degradation, offering a more durable and reliable option for large-scale immunization programs.
Licensing Contact: